



ASX ANNOUNCEMENT

Key Patent Granted in Japan

Fowl Adenoviral Delivery Vector patent granted in Asia's most important jurisdiction

16 November 2004, Sydney: Imugene (ASX: IMU) has been granted a key patent for its *Fowl Adenoviral Delivery Vector* in Japan. The *Fowl Adenoviral Delivery Vector* is the basis of all Imugene's poultry vaccines including one of the company's lead products, the *Poultry Productivity Enhancer* and the *Avian Influenza Vaccine*.

Imugene Managing Director, Dr Warwick Lamb commented, "The grant of this key patent is very significant because Japan is a key high value market for our products. Japanese patents have also historically set strong patent precedents in other Asian countries.

"Imugene has retained the right to sell the *Poultry Productivity Enhancer* in Australia, New Zealand and Japan and this patent completes patent coverage over these territories. Further granting of the *Fowl Adenoviral Delivery Vector* patent throughout Asia will strengthen commercial protection of Imugene's pending *Avian Influenza Vaccine*".

END

More information:

Dr Warwick Lamb,
Imugene's Managing Director
+61 2 9870 7330

Mr Graham Dowland,
Imugene's Executive Chairman
+61 8 9322 9189

Mr Rudi Michelson
Monsoon Communications
+61 3 9620 3333

ABOUT IMUGENE:

Imugene specialises in commercialising animal health products for production animals and pets.

Imugene's products safely prevent disease and reduce or eliminate antibiotics and harmful chemicals in animals. Animal antibiotics and chemicals in the human food chain have been linked to the emergence of dangerous resistant bacteria in people and food residues.

Imugene owns the worldwide rights to two platform technologies. The **Receptor Mimic Technology** for gastrointestinal diseases of pigs and potentially all other animal species. Secondly, the **Adenoviral Vector Delivery System** for pigs and poultry delivers Imugene's highly effective *poultry productivity enhancer*.

Imugene's poultry and pig portfolio is targeting a worldwide US\$3 billion annual market and replace existing chemical and antibiotic products. Consumer demands for residue free food and health regulatory pressures will bolster Imugene's prospects.

Visit the Imugene Website: www.imugene.com